{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114757","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.009580+00:00","generated_at":"2026-06-08T21:06:46.667851+00:00","sec_items":["3.03","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quoin to effect 1-for-60,000 reverse stock split on Nov 8; ADS ratio changes to 1:1","bullets":["Reverse split of ordinary shares at 1-for-60,000 ratio effective November 8, 2023.","Authorized ordinary share capital reduced from 6 trillion to 100 million shares.","Each ADS will represent one ordinary share post-split (previously 60,000 ordinary shares).","Shareholders approved three-year frequency for say-on-pay; board adopted that cycle."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114757","json":"https://secwatch.observer/filing/0001104659-23-114757.json","markdown":"https://secwatch.observer/filing/0001104659-23-114757.md","text":"https://secwatch.observer/filing/0001104659-23-114757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923114757/0001104659-23-114757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923114757/tm2330024d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:06:46.667851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}